Saxman S, Mann B, Canfield V, Loehrer P, Vokes E
Department of Medicine, Indiana University School of Medicine, Indianapolis 46202-5260, USA.
Am J Clin Oncol. 1998 Aug;21(4):398-400. doi: 10.1097/00000421-199808000-00016.
Forty patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated weekly with vinorelbine 30 mg/m2. Thirty-five patients received prior surgery, 20 prior chemotherapy, and 38 prior radiation therapy. Five patients were not evaluable for response and were assumed to be nonresponders. There were three confirmed responders (one complete response, two partial responses) for a response rate of 7.5% (95% confidence interval, 1.6%-20.4%). The median survival time for all patients was 5 months (range, 0.5-50 months), the median progression-free survival time was 2 months (range, 1-49 months). The most common toxicity was myelosuppression, with 60% of patients experiencing grade 3 or higher leukopenia. There was one treatment-related death resulting from sepsis. Vinorelbine has minimal activity in patients with SCCHN that does not exceed that of other currently used agents.
40例局部晚期、复发或转移性头颈部鳞状细胞癌（SCCHN）患者每周接受30mg/m²长春瑞滨治疗。35例患者曾接受过手术，20例曾接受过化疗，38例曾接受过放疗。5例患者无法评估疗效，被视为无反应者。有3例确认有反应者（1例完全缓解，2例部分缓解），反应率为7.5%（95%置信区间，1.6%-20.4%）。所有患者的中位生存时间为5个月（范围，0.5-50个月），中位无进展生存时间为2个月（范围，1-49个月）。最常见的毒性是骨髓抑制，60%的患者出现3级或更高等级的白细胞减少。有1例因败血症导致的治疗相关死亡。长春瑞滨在SCCHN患者中的活性极小，不超过其他目前使用的药物。
